-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: The innovative drug GST-HG121 for hepatitis B treatment is a surface antigen (HBsAg) inhibitor for hepatitis B.
August 27, 2020, Fujian Guangshengtang Pharmaceutical Co., Ltd. announced that it had received two Clinical Trial Approval Notices issued by the State Drug Administration (the "National Drug Administration") regarding the hepatitis B treatment innovation drug HBsAg inhibitor GST-HG121.
hepatitis B treatment innovative drug GST-HG121 is a hepatitis B surface antigen (HBsAg) inhibitor, is the company's hepatitis B clinical cure roadmap "peak plan" an important component.
GST-HG121 series of compounds have been patented internationally through the PCT channel and have been granted patents for compound inventions in 8 countries, including China, Japan, Korea, and Europe.
GST-HG121 clinical trial application was accepted by the National Drug Administration on June 16, 2020, acceptance number: CXHL2000290, CXHL2000291, CXHL2000292, CXHL2000293, registration classification: Chemicals 1 category.
clinical trial applications for CXHL2000290 and CXHL2000291 have been approved.
hepatitis B (HBV) is an infectious disease caused by hepatitis B virus (HBV), mainly hepatitis lesions and which can cause multi-organ damage.
B is a disease mainly in Asian and African populations such as China.
according to the World Health Organization's Global Hepatitis Report 2017, there are approximately 257 million people living with HBV worldwide.
According to the Guidelines for the Prevention and Control of Chronic Hepatitis B (2019 edition), China is a highly infected area of hepatitis B virus, the prevalence rate of hepatitis B virus in the general population of China is currently 5% to 6%, chronic hepatitis B infection of about 70 million cases, of which about 20 million to 30 million cases of chronic hepatitis B patients.
present, hepatitis B treatment drugs are divided into two main categories: nucleosides (acids) and interferons, neither can effectively remove hepatitis B virus to achieve clinical cure for the purpose of drug suspension.
, no drugs or combinations have been approved worldwide for hepatitis B cure.
cure of hepatitis B is a worldwide problem.
.
